US FDA shuffles roles at Office of Drug Evaluation 1 to improve decision making
This article was originally published in SRA
Robert Temple is giving up his role as acting director of the US Food Drug Administration's Office of Drug Evaluation 1 (ODE1) so that he can devote more time and his "vast expertise" to his other role as the deputy director for clinical science, the agency has announced1.
You may also be interested in...
A simplified process for registering and evaluating clinical trials promised by the EU Clinical Trial Regulation is finally set to become a reality.
As part of efforts to “renovate” its good clinical practice (GCP) framework, the International Council for Harmonisation has framed new overarching GCP principles that can be applied to diverse trial types and data sources.
The 2021 work plan of PIC/S, the international group of pharmaceutical inspectorates, includes renewed efforts to carry out projects that could not be completed due to the coronavirus pandemic.